<DOC>
	<DOCNO>NCT02095938</DOCNO>
	<brief_summary>1 . Study rationale - Nielsen et al report 6 week amisulpride treatment , patient schizophrenia showed increase anticipation-related functional MRI signal . This suggest amisulpride could affect brain structure response amisulpride could associate brain structure see previous study treatment response antipsychotic brain structure . But date , study examine impact brain structure alteration amisulpride treatment schizophrenia potential clinical significance . 2 . Study Objectives 2-1 . Primary : To show difference baseline brain structure structural MRI Solian® treatment responder non-responders 2-2 . Secondary : To show difference baseline polymorphism COMT BDNF molecular genetic analysis Solian® treatment responder non-responders responder define PANSS . To find correlate baseline brain structure symptom severity schizophrenia baseline ; symptom severity define CGI-S PANSS . To assess psychotic symptom improvement 8th week Solian® treatment use PANSS , SANS , SAPS CGI . To assess safety 8th week Solian® treatment Barnes Akathisia Scale , Simpson-Angus scale vital sign . To report serious adverse event within 24hrs regardless relationship investigational product . 3 . Study Design : Prospective/ Open label/ Interventional/ Controlled 4 . Evaluation Criteria : 5-1 . Primary endpoint : Brain structure structural MRI observe treatment start . Based clinical response treatment , patient divide two different group follow baseline brain structure compare . Treatment responder non-responders . 5-2 . Secondary endpoint : The relationship baseline brain structure symptom severity schizophrenia . Severity determine CGI-S PANSS baseline . The difference polymorphisms COMT BDNF molecular genetic analysis use patient ' peripheral blood , especially leukocytes , treatment responder non-responders . Efficacy - PANSS , SANS , SAPS , CGI . Safety - Barnes akathisia scale , Simpson-Angus scale , Vital sign</brief_summary>
	<brief_title>Association Amisulpride Response Schizophrenia With Brain Image</brief_title>
	<detailed_description>1 . Study rationale 1-1 . - Predicting treatment response antipsychotic drug schizophrenia patient issue psychiatry . However , clear finding structural magnetic resonance imaging ( MRI ) brain gray matter volume white matter connectivity , related treatment response antipsychotic drug . - The cognitive behavioural symptom patient schizophrenia hypothesize involve disruption neuronal interaction result dysfunctional cognitive integration ( Friston et al. , 1995 , 1996 ) . This hypothesis support report decrease white matter anatomic connection ( Mitelman et al . 2006 ; Skudlarski et al . 2010 ; Zalesky et al . 2011 ) brain structure alteration , especially decrease volume specific brain region patient schizophrenia . Several study brain connectivity show functional connectivity depend strongly underlying anatomic structure ( Sporns O et al . 2004 ) . At anatomic level , pathology schizophrenia relate wide range anatomic abnormality , include ventricular enlargement , associate anomalous neurodevelopment neurodegenerative alteration ( Shenton ME et al 2001 ) . And schizophrenia likely result general specific localize change grey white matter ( Knochel C et al . 2012 ; Konrad A et al . 2008 ) . Savas HA et al . find responder risperidone great hippocampal volume patient fail respond risperidone ( Savas HA et al. , 2002 ) . Vicente M et al . find inverse association striatal size degree clinical improvement , direct association degree insular volume deficit improvement . The non-responders risperidone olanzapine show significant decrease leave rectal gyrus compare responder group . ( Vicente M et al. , 2010 ) . - Nielsen et al report 6 week amisulpride treatment , patient schizophrenia showed increase anticipation-related functional MRI signal ( Nielsen et al. , 2012 ) . This suggest amisulpride could affect brain structure response amisulpride could associate brain structure see previous study treatment response antipsychotic brain structure . But date , study examine impact brain structure alteration amisulpride treatment schizophrenia potential clinical significance.. 2 . Study type : Clinical Study Phase IV 3 . Number center : single center Korea 4 . Number subject : N= 20 patient 5 . Study duration date ( format date : dd/mmm/yyyy ) 5-1 . Protocol plan date : 01/Apr/2013 5-2 . First patient In : 01/Nov/2013 5-3 . Last patient In : 01/Oct/2015 5-4 . Last patient Out : 01/Dec/2015 5-5 . Estimated enrollment duration : 2 year 5-6 . Estimated average treatment duration : 8 week 5-7 . Database lock plan date : 15/Dec/2015 5-8 . Estimated Report/Publication date : 31/Dec/2015 6 . Indication : Schizophrenia 7 . Study Objectives ( Primary / Most Important Secondary ) : 7-1 . Primary : To show difference baseline brain structure structural MRI Solian® treatment responder non-responders 7-2 . Secondary : - To show difference baseline polymorphism COMT BDNF molecular genetic analysis Solian® treatment responder non-responders ; responder define PANSS - To find correlate baseline brain structure symptom severity schizophrenia baseline ; symptom severity define CGI-S PANSS - To assess psychotic symptom improvement 8th week Solian® treatment use positive negative syndrome scale ( PANSS ) , scale assessment negative symptom ( SANS ) , scale assessment positive symptom ( SAPS ) clinical global impression scale ( CGI ) - To assess safety 8th week Solian® treatment Barnes Akathisia Scale , Simpson-Angus scale vital sign - To report serious adverse event ( SAE ) within 24hrs regardless relationship investigational product . SAE expedite report complete include : death , Requiring/prolonging hospitalization , Congenital anomaly/Birth defect , Life-threatening , Persistent/significant disability/incapacity , A procedure result symptomatic , consider investigator clinically significant meaningful lead permanent investigational product discontinuation require corrective treatment , A symptomatic overdose , A pregnancy , AESI ( adverse event special interest immediate notification ) AEs ( serious non-serious ) need monitor , document , manage pre-specified manner describe protocol . 8 . Inclusion Criteria : 8-1. 21 60 year age 8-2. diagnosed schizophrenia , base Structured Clinical Interview DSM-IV ( SCID ) 8-3. first second episode schizophrenia patient 8-4. presence positive negative symptom , result illness least mild severity ( ≥3 Clinical Global Impression ( CGI ) severity scale 9 . Exclusion Criteria : 9-1. evidence organic mental disorder mental retardation 9-2. severe drug alcohol dependence require inpatient treatment and/or detoxification 9-3. condition , serious medical condition , history bipolar schizoaffective disorder , suicidality , possibility pregnancy , lactation , inability/unwillingness use contraception 9-4. contraindicated Solian® product label 10 . Study Design : Prospective/ Open label/ Interventional/ Controlled 11 . Treatments : 11-1 . Study medication - Solian® comparator medication . 11-2 . Amisulpride ( Solian ) orally administer twice daily meal intake 8 week . Patients initially receive low dose amisulpride ( 200-400mg/day ) . The dosage may adjust 400 800mg/day accord clinical decision treat physician . 11-3 . For efficacy assessment , psychotic symptom assess baseline 8th week psychiatrist positive negative syndrome scale ( PANSS ) , scale assessment negative symptom ( SANS ) , scale assessment positive symptom ( SAPS ) clinical global impression scale ( CGI ) . 11-4 . For safety assessment , Barnes Akathisia Scale , Simpson-Angus scale vital sign assess 8th week treatment . 11-5 . Treatment responder define patient whose PANSS score reduction 30 % patient whose PANSS score decrease le 30 % assigned non-responder group . 11-6 . The investigator evaluate difference gray matter volume white matter connectivity responders non-responders amisulpride image brain 3T magnetic resonance imaging ( MRI ) use voxel-based morphometry ( VBM ) tract-based spatial statistic ( TBSS ) baseline . To examine possible association specific brain region response amisulpride , investigator use method base definition region interest ( ROIs ) . 11-7 . The investigator evaluate polymorphism COMT BDNF molecular genetic analysis use patient ' peripheral blood , especially leukocytes baseline . One-way analysis variance ( ANOVA ) use assess variation clinical symptom cognitive function accord COMT BDNF polymorphism . 12 . Evaluation Criteria : 12-1 Primary endpoint - Brain structure structural MRI observe treatment start . Based clinical response treatment , patient divide two different group follow baseline brain structure compare : - Treatment responder non-responders ; Treatment response define patient whose PANSS score reduce 30 % non-responder patient whose PANSS score decrease le 30 % 8 week baseline . 12-2 Secondary endpoint - The relationship baseline brain structure symptom severity schizophrenia ; Severity determine CGI-S PANSS baseline . - The difference polymorphisms COMT BDNF molecular genetic analysis use patient ' peripheral blood , especially leukocytes , treatment responder non-responders - Efficacy : PANSS , SANS , SAPS , CGI baseline 8th week - Safety : Barnes akathisia scale , Simpson-Angus scale , Vital sign 8th week 13 . Study Budget 13-1 . Total Study Cost ( euro ) : 13,848 euro ( 1 EUR = 1445 KRW ) 13-2 . Y ( year Study Outline approval ) : 5,539 EUR 13-3 . Y+1 : 5,539 EUR 13-4 . Beyond Y+1 : 2,770 EUR</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Sultopride</mesh_term>
	<mesh_term>Sulpiride</mesh_term>
	<criteria>21 60 year age diagnose schizophrenia , base Structured Clinical Interview DSMIV ( SCID ) first second episode schizophrenia patient presence positive negative symptom , result illness least mild severity ( ≥3 Clinical Global Impression ( CGI ) severity scale evidence organic mental disorder mental retardation severe drug alcohol dependence require inpatient treatment and/or detoxification condition , serious medical condition , history bipolar schizoaffective disorder , suicidality , possibility pregnancy , lactation , inability/unwillingness use contraception contraindicate Solian® product label</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>brain structure</keyword>
	<keyword>treatment response</keyword>
	<keyword>solian</keyword>
	<keyword>gene</keyword>
	<keyword>mri</keyword>
</DOC>